Company Profile
Assembly Biosciences Stock Price, News & Catalysts
- Ticker:
- ASMB
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
25.34 USD (-0.55%)
Close
Last updated: September 17, 2026
485M USD
Market cap
Why the stock is moving
As of Sep 17, 2026, ASMB closed down 0.55% at $25.34. No new same-company headline was identified in the current news window.
Company overview
Antiviral Small Molecules
Assembly Biosciences develops oral small-molecule therapies for serious viral diseases. Its portfolio targets viral replication mechanisms with the goal of improving suppression or enabling finite treatment.
Recurrent Genital Herpes
ABI-5366 and ABI-1179 are helicase-primase inhibitors that have completed Phase 1b studies in recurrent genital herpes. These programs are partnered with Gilead for subsequent development planning.
Hepatitis Delta Program
ABI-6250 is an oral small-molecule entry inhibitor for chronic hepatitis delta virus infection and has completed chronic toxicology studies supporting Phase 2 development.
Future catalysts
- Initiation of a Phase 2 study of ABI-6250 in chronic hepatitis delta by the end of 2026.
- Initiation of the Gilead-led Phase 2 GS-1179 study in recurrent genital herpes by the end of 2026.
- Initiation of a Phase 2 ABI-6250 study in cholestatic liver diseases in the first quarter of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Assembly Biosciences (ASMB)?
Assembly Biosciences (ASMB) most recently closed at 25.34 USD, a -0.55% move versus the previous session.
What is the market cap of Assembly Biosciences (ASMB)?
Assembly Biosciences currently has a market capitalization of 485M USD on BioPharmSignal.
What does Assembly Biosciences do?
Antiviral Small Molecules Assembly Biosciences develops oral small-molecule therapies for serious viral diseases. Its portfolio targets viral replication mechanisms with the goal of improving suppression or enabling finite treatment. Recurrent Genital Herpes ABI-5366 and ABI-1179 are helicase-primase inhibitors that have completed Phase 1b studies in...
On which exchange is ASMB stock listed?
Assembly Biosciences (ASMB) is associated with NASDAQ, United States, Biopharma.
What is ABI-5366?
Recurrent Genital Herpes ABI-5366 and ABI-1179 are helicase-primase inhibitors that have completed Phase 1b studies in recurrent genital herpes.
Which conditions is Assembly Biosciences targeting with ABI-5366?
Antiviral Small Molecules Assembly Biosciences develops oral small-molecule therapies for serious viral diseases. Its portfolio targets viral replication mechanisms with the goal of improving suppression or enabling finite treatment. Recurrent Genital Herpes ABI-5366 and ABI-1179 are helicase-primase inhibitors that have completed Phase 1b studies in...
How does Assembly Biosciences describe recent progress with ABI-5366?
Initiation of a Phase 2 study of ABI-6250 in chronic hepatitis delta by the end of 2026. Initiation of the Gilead-led Phase 2 GS-1179 study in recurrent genital herpes by the end of 2026. Initiation of a Phase 2 ABI-6250 study in cholestatic liver diseases in the first quarter of 2027.
What is ABI-1179?
Recurrent Genital Herpes ABI-5366 and ABI-1179 are helicase-primase inhibitors that have completed Phase 1b studies in recurrent genital herpes.